PUBG Mobile's lifetime revenue hits $3bn, India tops download chart
by Maria Thomas
Updated Jul 04, 2020
With people staying home owing to the Covid-19 pandemic and lockdowns, the PUBG revenues hit a record high of $270 million (around Rs 2,021 crore) in March, reveals data from analytics firm Sensor Tower.
PUBG is not banned in India as it is not entirely Chinese. The game has been created and managed by Bluehole which is a South Korean organisation.
After PUBG became popular, Tencent -- a Chinese conglomerate -- joined hands with Bluehole to market the product in China and started handling a large portion of its distribution. The game is distributed in India by Tencent Holdings. The game did not feature in the banned list due to its mixed ownership, since it's not entirely Chinese.
According to Sensor Tower data, in 2020, while the Garena offering collected over $300 million (roughly Rs. 2,245 crore), Knives Out from NetEase generated over $260 million (roughly Rs. 1,946 crore) in revenue.
Following them is Activision's Call of Duty: Mobile that turned in a revenue of $220 million (around Rs 1,646 crore).
Google Play accounts for the lion's share of downloads, at 65 per cent of all installs, while the App Store represents 35 per cent of the total.
PUBG Mobile, thanks to the release of ‘Game For Peace' in China, has been a wild success internationally.
Related Articles
- Optical Illusion Brain Test: If you have Sharp Eyes Find the Number 442 in 20 Secs
- London-based firm Nothing to release its Phone (2)
- Covid will continue to cause mini-waves, not become seasonal yet: Scientists
- Hackers offering crypto accounts for as low as $30 on darknet
- Reddit's new feature to allow users to share its content on other platforms
- Surgical masks can help kids fight respiratory infections: Study
- LinkedIn's new AI feature to write messages to hiring team
- Microsoft introduces Xbox Game Pass' new Friend Referral programme
- Disbursed over Rs 31 cr in claims to delivery partners in FY22-23: Swiggy
- India emerging as favourable destination for clinical trials: Report